Bioverativ

ELOCTATE

Manufacturer:

Bioverativ

Eloctate HCPCS:

J7205

HCPCS Code Descriptor:

Injection, factor viii fc fusion protein (recombinant), per iu

Category:

J Code

Eloctate NDCs:

71104-0810-01, 71104-0808-01, 71104-0809-01, 71104-0804-01, 71104-0805-01, 71104-0807-01, 71104-0806-01, 71104-0803-01, 71104-0802-01, 71104-0801-01

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Eloctate:

ELOCTATE is a Hematology drug manufactured by Bioverativ and administered via the Intravenous route of administration. The J Code: J7205 is aligned to the drug ELOCTATE.

ELOCTATE is a recombinant, DNA-derived Factor VIII concentrated commonly used to treat hemophilia. It temporarily replaces the Factor VIII that patients with hemophilia are missing with a demonstrated 3-4 times longer half-life than similar Factor VIII substitutes. ELOCTATE (J7205) is indicated for use in children and adults to reduce the frequency of bleeding episodes, as an on-demand treatment for bleeding episodes, and as a way to manage bleeding in a perioperative setting. Patient assistance for this medication may be available through Eloctate.

ACCESS PRICING AND MORE BY REGISTERING

J7205 Added Date:

January 1, 2016

J7205 Effective Date:

January 1, 2016

J7205 Termination Date:

HCPCS Active

Eloctate billing and coding information can be found through Bioverativ at the link below:
Eloctate patient assistance information can be found through MyELOCTATE at the URL: https://www.eloctate.com/resources/financial-assistance.aspx
ELOCTATE prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for ELOCTATE. Please check back in a few weeks.